JP6561128B2 - Ｃｎｓ疾患を治療するための縮合ジヒドロ−４ｈ−ピラゾロ［５，１−ｃ］［１，４］オキサジニル化合物およびアナログ - Google Patents
Ｃｎｓ疾患を治療するための縮合ジヒドロ−４ｈ−ピラゾロ［５，１−ｃ］［１，４］オキサジニル化合物およびアナログ Download PDFInfo
- Publication number
- JP6561128B2 JP6561128B2 JP2017542400A JP2017542400A JP6561128B2 JP 6561128 B2 JP6561128 B2 JP 6561128B2 JP 2017542400 A JP2017542400 A JP 2017542400A JP 2017542400 A JP2017542400 A JP 2017542400A JP 6561128 B2 JP6561128 B2 JP 6561128B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- certain embodiments
- disorder
- pharmaceutically acceptable
- esi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C)CC(CC1(C)CC(C)C)C1OC(C)(*)c1c(CCCCC2)c2n[n]1 Chemical compound CC(C)CC(CC1(C)CC(C)C)C1OC(C)(*)c1c(CCCCC2)c2n[n]1 0.000 description 9
- JDWTZUOPXWNHHL-KHPPLWFESA-N B/C=C(/C)\Cc1cc2n[n](CCOC(C)=O)c(C(C)=O)c2cc1 Chemical compound B/C=C(/C)\Cc1cc2n[n](CCOC(C)=O)c(C(C)=O)c2cc1 JDWTZUOPXWNHHL-KHPPLWFESA-N 0.000 description 1
- UKAIZYYIUFCBAI-UHFFFAOYSA-N C(CNCC1)C1C1OCC[n]2nc(cccc3)c3c12 Chemical compound C(CNCC1)C1C1OCC[n]2nc(cccc3)c3c12 UKAIZYYIUFCBAI-UHFFFAOYSA-N 0.000 description 1
- JQRACJURNGSMFH-UHFFFAOYSA-N CC(C)(C)OC(N(C)CC1OCC[n]2nc(cc[s]3)c3c12)=O Chemical compound CC(C)(C)OC(N(C)CC1OCC[n]2nc(cc[s]3)c3c12)=O JQRACJURNGSMFH-UHFFFAOYSA-N 0.000 description 1
- XCNVQODXKPZPQB-MYJWUSKBSA-N CC(C)(C)OC(N(CCOC1)[C@@H]1C1OCC[n]2nc(cccc3)c3c12)=O Chemical compound CC(C)(C)OC(N(CCOC1)[C@@H]1C1OCC[n]2nc(cccc3)c3c12)=O XCNVQODXKPZPQB-MYJWUSKBSA-N 0.000 description 1
- GICXECLEZHKNNF-WSAYOVPUSA-N CC(OCCN/C(/C(CBr)=O)=C(/C=CC=C1)\C1=N)=O Chemical compound CC(OCCN/C(/C(CBr)=O)=C(/C=CC=C1)\C1=N)=O GICXECLEZHKNNF-WSAYOVPUSA-N 0.000 description 1
- VTLCHUJSWRRPHX-LNUXAPHWSA-N CC([C@H]1OCC[n]2nc(cccc3)c3c12)N(C)C Chemical compound CC([C@H]1OCC[n]2nc(cccc3)c3c12)N(C)C VTLCHUJSWRRPHX-LNUXAPHWSA-N 0.000 description 1
- MOKYIEZXRYOQIQ-UHFFFAOYSA-N CC(c1c(cccc2)c2n[n]1CCO)=O Chemical compound CC(c1c(cccc2)c2n[n]1CCO)=O MOKYIEZXRYOQIQ-UHFFFAOYSA-N 0.000 description 1
- LZHYQJRYRFUPKO-UHFFFAOYSA-N CNCC1OCC[n]2nc(cc[s]3)c3c12 Chemical compound CNCC1OCC[n]2nc(cc[s]3)c3c12 LZHYQJRYRFUPKO-UHFFFAOYSA-N 0.000 description 1
- BCABNEKXMQCIKL-UHFFFAOYSA-N CNCC1OCC[n]2nc(ccc(Cl)c3)c3c12 Chemical compound CNCC1OCC[n]2nc(ccc(Cl)c3)c3c12 BCABNEKXMQCIKL-UHFFFAOYSA-N 0.000 description 1
- AEMZCTFSFHDKQX-UHFFFAOYSA-N COC1OCC[n]2nc(ccc(F)c3)c3c12 Chemical compound COC1OCC[n]2nc(ccc(F)c3)c3c12 AEMZCTFSFHDKQX-UHFFFAOYSA-N 0.000 description 1
- FJHUOXBTNADXDT-UHFFFAOYSA-N C[N](C)(CC1OCC[n]2nc(cc(cc3)F)c3c12)Cl Chemical compound C[N](C)(CC1OCC[n]2nc(cc(cc3)F)c3c12)Cl FJHUOXBTNADXDT-UHFFFAOYSA-N 0.000 description 1
- HVNMALYRMKZJJC-UHFFFAOYSA-N OCC[n]1nc(ccc(F)c2)c2c1C=O Chemical compound OCC[n]1nc(ccc(F)c2)c2c1C=O HVNMALYRMKZJJC-UHFFFAOYSA-N 0.000 description 1
- YKKZOHDZPPHABF-UHFFFAOYSA-N OCC[n]1nc(cccc2)c2c1 Chemical compound OCC[n]1nc(cccc2)c2c1 YKKZOHDZPPHABF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019134260A JP6928629B2 (ja) | 2015-02-11 | 2019-07-22 | Ｃｎｓ疾患を治療するための縮合ジヒドロ−４ｈ−ピラゾロ［５，１−ｃ］［１，４］オキサジニル化合物およびアナログ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115043P | 2015-02-11 | 2015-02-11 | |
| US62/115,043 | 2015-02-11 | ||
| PCT/US2016/017527 WO2016130790A1 (en) | 2015-02-11 | 2016-02-11 | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019134260A Division JP6928629B2 (ja) | 2015-02-11 | 2019-07-22 | Ｃｎｓ疾患を治療するための縮合ジヒドロ−４ｈ−ピラゾロ［５，１−ｃ］［１，４］オキサジニル化合物およびアナログ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018505204A JP2018505204A (ja) | 2018-02-22 |
| JP2018505204A5 JP2018505204A5 (enExample) | 2019-03-28 |
| JP6561128B2 true JP6561128B2 (ja) | 2019-08-14 |
Family
ID=55456906
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542400A Expired - Fee Related JP6561128B2 (ja) | 2015-02-11 | 2016-02-11 | Ｃｎｓ疾患を治療するための縮合ジヒドロ−４ｈ−ピラゾロ［５，１−ｃ］［１，４］オキサジニル化合物およびアナログ |
| JP2019134260A Expired - Fee Related JP6928629B2 (ja) | 2015-02-11 | 2019-07-22 | Ｃｎｓ疾患を治療するための縮合ジヒドロ−４ｈ−ピラゾロ［５，１−ｃ］［１，４］オキサジニル化合物およびアナログ |
| JP2021129696A Ceased JP2021183624A (ja) | 2015-02-11 | 2021-08-06 | Ｃｎｓ疾患を治療するための縮合ジヒドロ−４ｈ−ピラゾロ［５，１−ｃ］［１，４］オキサジニル化合物およびアナログ |
| JP2022193341A Ceased JP2023036611A (ja) | 2015-02-11 | 2022-12-02 | Ｃｎｓ疾患を治療するための縮合ジヒドロ－４ｈ－ピラゾロ［５，１－ｃ］［１，４］オキサジニル化合物およびアナログ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019134260A Expired - Fee Related JP6928629B2 (ja) | 2015-02-11 | 2019-07-22 | Ｃｎｓ疾患を治療するための縮合ジヒドロ−４ｈ−ピラゾロ［５，１−ｃ］［１，４］オキサジニル化合物およびアナログ |
| JP2021129696A Ceased JP2021183624A (ja) | 2015-02-11 | 2021-08-06 | Ｃｎｓ疾患を治療するための縮合ジヒドロ−４ｈ−ピラゾロ［５，１−ｃ］［１，４］オキサジニル化合物およびアナログ |
| JP2022193341A Ceased JP2023036611A (ja) | 2015-02-11 | 2022-12-02 | Ｃｎｓ疾患を治療するための縮合ジヒドロ－４ｈ－ピラゾロ［５，１－ｃ］［１，４］オキサジニル化合物およびアナログ |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US9758529B2 (enExample) |
| EP (3) | EP3256476B1 (enExample) |
| JP (4) | JP6561128B2 (enExample) |
| KR (1) | KR102623321B1 (enExample) |
| CN (2) | CN107567454B (enExample) |
| AU (4) | AU2016219247B2 (enExample) |
| BR (1) | BR112017017349B1 (enExample) |
| CA (1) | CA2976092A1 (enExample) |
| DK (1) | DK3256476T3 (enExample) |
| EA (1) | EA201791802A1 (enExample) |
| ES (1) | ES2712627T3 (enExample) |
| IL (2) | IL253907B (enExample) |
| MX (1) | MX371197B (enExample) |
| NZ (1) | NZ734972A (enExample) |
| PH (1) | PH12017501423A1 (enExample) |
| PL (1) | PL3256476T3 (enExample) |
| PT (1) | PT3256476T (enExample) |
| SG (1) | SG11201706516WA (enExample) |
| UA (1) | UA123262C2 (enExample) |
| WO (1) | WO2016130790A1 (enExample) |
| ZA (1) | ZA201706074B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9758529B2 (en) * | 2015-02-11 | 2017-09-12 | Sunovion Pharmaceuticals Inc. | Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders |
| SG10202100724UA (en) | 2016-07-29 | 2021-03-30 | Sunovion Pharmaceuticals Inc | Compounds and compositions and uses thereof |
| BR112019001407A2 (pt) | 2016-07-29 | 2019-07-09 | Sunovion Pharmaceuticals Inc. | compostos e composições e usos dos mesmos |
| KR101753092B1 (ko) | 2016-12-14 | 2017-07-04 | 성일하이텍(주) | 리튬 함유 폐액으로부터 인산리튬 제조방법 |
| US10850989B2 (en) | 2016-12-20 | 2020-12-01 | Sungeel Hitech Co., Ltd. | Method for preparing solid lithium salt from lithium solution |
| AU2018258117A1 (en) | 2017-04-24 | 2019-12-12 | Chase Therapeutics Corporation | Compositions and method for treating depression |
| AU2018290889B2 (en) | 2017-06-30 | 2024-06-27 | Alto Neuroscience, Inc. | NK-1 antagonist compositions and methods for use in treating depression |
| MX2020000523A (es) | 2017-08-02 | 2020-08-20 | Sunovion Pharmaceuticals Inc | Compuestos de isocromano y usos de los mismos. |
| US20190375764A1 (en) | 2018-06-07 | 2019-12-12 | Sunovion Pharmaceuticals Inc. | Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| JP7703449B2 (ja) | 2019-03-14 | 2025-07-07 | スミトモ・ファーマ・アメリカ・インコーポレイテッド | イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物 |
| TW202237622A (zh) | 2020-12-04 | 2022-10-01 | 美商蘇諾維恩藥業公司 | 雜環化合物的鹽及其晶型、製備方法、治療用途與醫藥組合物 |
| US20240158416A1 (en) * | 2021-04-08 | 2024-05-16 | Sumitomo Pharma America, Inc. | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders |
| US20240417378A1 (en) * | 2021-10-11 | 2024-12-19 | Baylor College Of Medicine | G-protein-coupled receptor regulators and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3995052A (en) * | 1973-07-09 | 1976-11-30 | Ayerst Mckenna And Harrison Ltd. | Indenopyran- and indenothiopyranalkylamines III in the treatment of depression |
| US4041169A (en) * | 1975-03-05 | 1977-08-09 | Ayerst Mckenna And Harrison Ltd. | Pharmaceutical method for using pyrano-and thiopyranoindole derivatives |
| CN101421280A (zh) * | 2006-04-12 | 2009-04-29 | 惠氏公司 | 作为5-羟色胺-6配体的经取代二氢[1,4]噁嗪并[2.3.4-hi]吲唑衍生物 |
| AU2010214101A1 (en) * | 2009-02-11 | 2011-09-01 | Sunovion Pharmaceuticals Inc. | Histamine H3 inverse agonists and antagonists and methods of use thereof |
| CN104193761B (zh) * | 2009-12-04 | 2017-10-17 | 桑诺维恩药品公司 | 多环化合物及其使用方法 |
| EA026134B1 (ru) * | 2010-12-16 | 2017-03-31 | Ф. Хоффманн-Ля Рош Аг | Трициклические ингибиторы pi3k и способы их применения |
| CA2847095A1 (en) * | 2011-10-05 | 2013-04-11 | F. Hoffmann-La Roche Ag | Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists |
| US9365588B2 (en) * | 2011-11-04 | 2016-06-14 | Vertex Pharmaceuticals Incorporated | Benzoxazines as modulators of ion channels |
| US9403835B2 (en) * | 2011-12-22 | 2016-08-02 | Ares Trading S.A. | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators |
| CA2876969A1 (en) | 2012-06-20 | 2013-12-27 | Vanderbilt University | Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors |
| JP2014214130A (ja) * | 2013-04-26 | 2014-11-17 | 大正製薬株式会社 | ジヒドロイミダゾオキサゾール誘導体を含有する医薬 |
| US9758529B2 (en) * | 2015-02-11 | 2017-09-12 | Sunovion Pharmaceuticals Inc. | Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders |
| UA122222C2 (uk) * | 2015-02-11 | 2020-10-12 | Суновіон Фармасьютикалз Інк. | Сполуки 1-гетероцикліл-ізохроманілу і аналоги для лікування розладів цнс |
-
2016
- 2016-02-11 US US15/041,827 patent/US9758529B2/en not_active Expired - Fee Related
- 2016-02-11 PL PL16708260T patent/PL3256476T3/pl unknown
- 2016-02-11 JP JP2017542400A patent/JP6561128B2/ja not_active Expired - Fee Related
- 2016-02-11 BR BR112017017349-2A patent/BR112017017349B1/pt not_active IP Right Cessation
- 2016-02-11 SG SG11201706516WA patent/SG11201706516WA/en unknown
- 2016-02-11 EP EP16708260.1A patent/EP3256476B1/en active Active
- 2016-02-11 KR KR1020177025289A patent/KR102623321B1/ko active Active
- 2016-02-11 AU AU2016219247A patent/AU2016219247B2/en not_active Expired - Fee Related
- 2016-02-11 MX MX2017010362A patent/MX371197B/es active IP Right Grant
- 2016-02-11 EP EP21198192.3A patent/EP4006039B1/en active Active
- 2016-02-11 NZ NZ734972A patent/NZ734972A/en not_active IP Right Cessation
- 2016-02-11 CA CA2976092A patent/CA2976092A1/en active Pending
- 2016-02-11 WO PCT/US2016/017527 patent/WO2016130790A1/en not_active Ceased
- 2016-02-11 EA EA201791802A patent/EA201791802A1/ru unknown
- 2016-02-11 ES ES16708260T patent/ES2712627T3/es active Active
- 2016-02-11 DK DK16708260.1T patent/DK3256476T3/en active
- 2016-02-11 CN CN201680018684.5A patent/CN107567454B/zh not_active Expired - Fee Related
- 2016-02-11 CN CN202010051639.8A patent/CN111171047B/zh not_active Expired - Fee Related
- 2016-02-11 UA UAA201708954A patent/UA123262C2/uk unknown
- 2016-02-11 PT PT16708260T patent/PT3256476T/pt unknown
- 2016-02-11 EP EP18213435.3A patent/EP3539967A1/en not_active Withdrawn
-
2017
- 2017-08-02 US US15/666,719 patent/US20180057506A1/en not_active Abandoned
- 2017-08-08 IL IL253907A patent/IL253907B/en active IP Right Grant
- 2017-08-09 PH PH12017501423A patent/PH12017501423A1/en unknown
- 2017-09-06 ZA ZA2017/06074A patent/ZA201706074B/en unknown
-
2019
- 2019-05-06 US US16/403,734 patent/US20200024286A1/en not_active Abandoned
- 2019-07-22 JP JP2019134260A patent/JP6928629B2/ja not_active Expired - Fee Related
-
2020
- 2020-09-29 IL IL277658A patent/IL277658B/en unknown
- 2020-11-11 AU AU2020267209A patent/AU2020267209A1/en not_active Abandoned
-
2021
- 2021-02-19 US US17/179,477 patent/US20210300942A1/en not_active Abandoned
- 2021-08-06 JP JP2021129696A patent/JP2021183624A/ja not_active Ceased
-
2022
- 2022-10-28 AU AU2022259828A patent/AU2022259828A1/en not_active Abandoned
- 2022-12-02 JP JP2022193341A patent/JP2023036611A/ja not_active Ceased
-
2024
- 2024-06-24 AU AU2024204310A patent/AU2024204310A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6928629B2 (ja) | Ｃｎｓ疾患を治療するための縮合ジヒドロ−４ｈ−ピラゾロ［５，１−ｃ］［１，４］オキサジニル化合物およびアナログ | |
| JP7023994B2 (ja) | Ｃｎｓ疾患を治療するための１－複素環イソクロマニル化合物およびアナログ | |
| CN111183138A (zh) | 异色满化合物以及用途 | |
| HK40006461A (en) | Process for the preparation of fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds | |
| HK40073618B (en) | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders | |
| HK40073618A (en) | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders | |
| HK1241875B (en) | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders | |
| HK1241875A1 (en) | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders | |
| HK40078692B (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| HK40078692A (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190208 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190208 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20190304 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20190618 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190625 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190627 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190722 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6561128 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |